Finance

Lists
TRVI:NASDAQ
Trevi Therapeutics Inc
$18.81
-0.16%
(-0.030) 1D
$18.81
0.00% (0.00)
After hours
Closed: Aug 19, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRVI...
Open
$19.29
High
$19.30
Low
$18.50
Mkt. cap
2.68B
Avg. vol.
2.09M
Volume
0.00
52-wk high
$20.15
52-wk low
$6.93
EPS
-$0.34
Beta
1.03
Shares outstanding
142.48M
No. of employees
34
Open
$19.29
High
$19.30
Low
$18.50
Mkt. cap
2.68B
Avg. vol.
2.09M
Volume
0.00
52-wk high
$20.15
52-wk low
$6.93
EPS
-$0.34
Beta
1.03
Shares outstanding
142.48M
No. of employees
34
News stories
From web sources and news partners
About Trevi Therapeutics Inc
CEO-
Employees34
Founded2011
HeadquartersNew Haven, Connecticut, United States
SectorPharmaceutical industry
Websitetrevitherapeutics.com
Analyst ratings
Based on 10 analysts giving stock ratings to TRVI in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for TRVI in the last 3 months.
Highest
Current $18.81
$40.00 (+112.65%)
Average
$29.00 (+54.17%)
Lowest
$23.00 (+22.28%)
Analyst
Recommendation
Action
Price target
Projected
Date
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
$28.00
+48.9%
08/13/2026
Brandon Folkes
H.C. Wainwright
Buy
Maintained
$24.00
+27.6%
08/11/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
$23.00
+22.3%
08/10/2026
Serge Belanger
Needham
Buy
Maintained
$23.00
+22.3%
08/07/2026
Ryan Deschner
Raymond James
Buy
Maintained
$40.00
+112.7%
08/07/2026
Mayank Mamtani
B. Riley Securities
Buy
Initiated
$31.00
+64.8%
08/07/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$30.00
+59.5%
08/06/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$25.00
+32.9%
08/07/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
$30.00
+59.5%
08/07/2026
Conor MacKay
BMO Capital
Buy
Initiated
$36.00
+91.4%
07/21/2026
Evan Seigerman
BMO Capital
Buy
Initiated
$36.00
+91.4%
07/21/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$36.00
+91.4%
07/20/2026
William Wood
B. Riley Securities
Buy
Reiterated
$31.00
+64.8%
07/17/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$29.00
+54.2%
05/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10.08M
6.19M
9.94M
15.15M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.83M
4.03M
4.97M
5.36M
Operating expense
13.92M
10.22M
14.91M
20.51M
Total operating expenses
13.92M
10.22M
14.91M
20.51M
Operating income
-13.92M
-10.22M
-14.91M
-20.51M
Other non operating income
-2.00K
-15.00K
-
-
EBT including unusual items
-11.82M
-8.33M
-13.21M
-17.82M
EBT excluding unusual items
-11.82M
-8.33M
-13.21M
-17.82M
Income tax expense
-15.00K
-16.00K
-20.00K
-19.00K
Effective tax rate
0.13%
0.19%
0.15%
0.11%
Other operating expenses
-
-
-
-
Net income
-11.80M
-8.32M
-13.19M
-17.80M
Net profit margin
-
-
-
-
Earnings per share
-0.08
-0.06
-0.09
-0.11
Interest and investment income
2.10M
1.90M
1.70M
2.70M
Interest expense
-
-
-
-
Net interest expenses
2.10M
1.90M
1.70M
2.70M
Depreciation and amortization charges
-
-
-
-
EBITDA
-13.88M
-10.19M
-14.88M
-20.48M
Gain or loss from assets sale
-
7.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps